Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.I. F. Tannock, K C Murphy, A. J. Neville et al.|Journal of Clinical Oncology|1996Cited by 1.6k
Survival gains needed to offset persistent adverse treatment effects in localised prostate cancerMadeleine King, Bruce K. Armstrong, Rosalie Viney et al.|British Journal of Cancer|2012Cited by 49